IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia
Cobenfy, a co-formulation of xanomeline and trospium, is the first drug not acting on the dopaminergic system of the CNS approved for the treatment of schizophrenia by the FDA. Xanomeline is a muscarinic M1 and M4 receptor (CHRM1 and CHRM4) agonist whilst trospium is a peripherally active CHRM antag...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2024-12-01
|
| Serija: | Pharmacological Research |
| Teme: | |
| Online pristup: | http://www.sciencedirect.com/science/article/pii/S1043661824004559 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|